Finacea is light, easily absorbed, and is most often prescribed by dermatologists. In fact, FINACEA is prescribed primarily by dermatologists and it is considered by them to be a first-line treatment option for rosacea sufferers.
FINACEA is unique. Here are a few of its key features:
FINACEA is the first prescription gel approved by the FDA for treating the redness and the bumps and pimples associated with rosacea.
It contains azelaic acid, a naturally occurring active ingredient that is present in whole grains and in the skin.
It can be used in conjunction with non-irritating skin care products and cosmetics. It's a water-based gel that is fragrance-free (to help prevent allergic reactions), alcohol-free (to help prevent irritation and dryness), easily absorbed, and that penetrates deeply. It's perfect for daily use at home and on the go.
Unlike some topical medications whose effectiveness levels off after 8 weeks, in a medical trial, rosacea sufferers using FINACEA experienced a continuous decline in red bumps and pimples throughout 12 weeks of treatment.
Finacea is indicated for topical treatment of inflammatory papules and pustules of mild to moderate rosacea. Although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated.
Finacea is for dermatologic use only, and not for ophthalmic, oral, or intravaginal use. Finacea is contraindicated in individuals with a history of hypersensitivity to propylene glycol or any other component of the formulation. In clinical trials, sensations of burning/stinging/tingling occurred in 29% of patients, and itching in 11%, regardless of the relationship to therapy. Post-marketing safety—Skin: facial burning and irritation; Eyes: iridocyclitis on accidental exposure to the eye. There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with dark complexion, these patients should be monitored for early signs of hypopigmentation.
---------------------------------------